Learning Center

Neurological Diseases: An Unmet Frontier for Medical Technology

Solving the complex challenge of the human brain.

Traumatic Brain Injury
Parkinson's Disease
Huntingdon's Disease
Epilepsy
Chronic Major Depression
Brain Tumor
Dystonia
Alzheimer's Disease

Nearly 1 in 6 of world’s population suffer from neurological disorders

33"

It is estimated that a new case of Alzheimers appears every 33 seconds.

$760b

In America, neurological illnesses and mental disorders cost the US more than $760 billion a year.

12%

Neurological Conditions constitute 12% of total deaths globally.

The Blood-Brain Barrier

The blood-brain barrier (BBB) is the name given to the physical and biomolecular properties of cerebral blood vessels that combine to restrict mass transfer of many molecules, especially potentially dangerous ones, from the blood to brain tissue. The BBB both restricts and regulates exchange between blood and surrounding tissue to maintain a favorable environment for neuronal function regardless of metabolic activity, diet, and other factors that alter blood composition.

As a result of its physical and biomolecular properties, transport through the BBB is restricted to small, uncharged molecules such as oxygen and carbon dioxide, small lipophilic molecules that can move across cell membranes, including caffeine and ethanol, and compounds such as glucose, some amino acids, and a few other organics that are transferred using membrane-bound transporters mentioned above. Water is permeable to the BBB through water channels in the endothelial cells membranes.

Learn about our CNS delivery technologies

10 Advantages of Direct CNS Delivery

  • 1) Deliver high levels of a drug to target organ or subregion.
  • 2) Limit exposure to other organs.
  • 3) Deliver a complex dosing pattern.
  • 4) Bypass liver metabolism, degradation in blood.
  • 5) Bypass anatomical blockages (ex. blood-brain barrer).
  • 6) Greatly reduce effective drug dosage.
  • 7) Increase speed of drug effect.
  • 8) Ensure drug regimen compliance.
  • 9) Reduced drug manufacturing costs.
  • 10) Create new IP/extend life cycle.